Most switches to Descovy PrEP are probably unnecessary and some may be harmful
Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths
To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP
Large numbers now on Descovy PrEP in the United States
New once-a-week drug could be part of weekly oral treatment
Doravirine injections were safe and long-lasting, but did not reach therapeutic levels
Black people and women are under-represented in anti-HIV drug studies
Far fewer people would get PrEP in the US if generic TDF/FTC is replaced with Descovy (TAF/FTC), cost-effectiveness study finds
